Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    YXT.com

    MCap

    USD127m

    Last close

    USD23.43

    ▲ 20.23 (632.19%)

    Northern Data Group

    MCap

    EUR486m

    Last close

    EUR7.56

    ▲ 2.33 (44.59%)

    Bodycote

    MCap

    GBP1,572m

    Last close

    GBP9.23

    ▲ 173.00 (23.07%)

  • Sectors

    Sectors

  • Megatrends

    Megatrends

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Chosa (XSAT: CHOSA)

Last close As at 05/08/2026

SEK0.77

▲ 0.01 (1.32%)

Market capitalisation

SEK71m

Chosa Oncology (previously RhoVac) is a Danish biotech focused on the development of iCIP, a technology consisting of a cisplatin drug response predictor and a liposomal formulation of conventional cisplatin. iCIP has demonstrated encouraging clinical proof of concept from a Phase IIb study in breast cancer patients and Chosa is now looking for strategic partnerships to progress clinical development of the technology.

Latest Insights

View More

Healthcare | edison tv

CHOSA Oncology – executive interview

Healthcare | Update

Chosa Oncology — Making headway in precision oncology

Healthcare | Update

RhoVac — On the home straight

Healthcare | Outlook

RhoVac — Phase IIb BRaVac study results in H122

Market Data

Share Price SEK0.77
Market Cap SEK71m
52-Week High SEK2.20
52-Week Low SEK0.53
% Change 1M (3.8)
% Change 6M (3.4)
% Change 12M 40.9
Ave. Daily Volume 1yr 72,355
Visit Website

Sector

Healthcare

Equity Analyst

Key Management

  • Claus Frisenberg Pedersen

    CFO

  • Neil Goldsmith

    Chairman

  • Peter Buhl Jensen

    CEO

Share Price Chart

Update

Healthcare

RhoVac — Funded to execute Phase IIb study as planned

Initiation

Healthcare

RhoVac — Stopping metastasis in its tracks